Abstract
The transition from general guidelines to precision cardiovascular medicine requires tools that can model individual biological variance. This paper outlines the methodology of LipidLogic Pro v2.1, a simulation engine for predicting Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT) following intensified lipid-lowering therapy. The engine utilizes a kinetic-based meta-regression approach derived from the Cholesterol Treatment Trialists’ (CTT) Collaboration.
References
1. Baigent C, et al. (Cholesterol Treatment Trialists’ Collaboration). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267-1278
2. Cannon CP, et al. (IMPROVE-IT Investigators). Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.
3. Mach F, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.
4. Sabatine MS, et al. (FOURIER Steering Committee). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Khaing Mar Lwin, Mahmood Ahmad, Tomi, Ata Ul Hayee Sohail